Cartesian Therapeutics initiated with a Buy at BTIG

BTIG initiated coverage of Cartesian Therapeutics (RNAC) with a Buy rating and $42 price target Cartesian is pioneering the field of mRNA-based CART cell therapies for autoimmune disorders, the analyst tells investors in a research note. The firm says the company’s lead efforts are in myasthenia gravis, which has provided “important proof of concept for Descartes-08 with differentiated efficacy that looks progressive through long-term follow-up.” BTIG sees an attractive entry point for investors ahead of MG Phase 3 initiation in the first half of 2025.